news releases

14 June 2020

OncoImmune, Inc. Reports Progress on its Phase III Clinical Trial testing CD24Fc for Severe and Critical COVID-19



Category: News Releases

OncoImmune, Inc. reached an important milestone in its Phase III clinical trial testing the safety and clinical efficacy of CD24Fc for severe and critical COVID-19 patients (SAC-COVID) on June 9, 2020. The first 70 patients have been randomized and received either CD24Fc or placebo as the treatment for severe COVID-19. After reviewing the safety data, the Institutional Review Board has approved continuing enrollment while interim analysis occurs.

Current therapeutic strategies for COVID-19 include use of anti-viral therapies that block viral replication and non-anti-viral therapeutics that target host responses responsible for the destruction of host organs. Since many hospitalized patients have either largely cleared the SARS-CoV-2 virus or may have developed immunity to it, non-antiviral strategies have emerged as an important approach in treating severe and critical COVID-19 patients.

CD24Fc is a first-in-class biologic that fortifies an innate immune checkpoint against excessive inflammation caused by tissue-injuries. The Phase III trial has been opened at 10 medical centers nationwide and enrolls severe and critical COVID-19 patients that either require supplemental oxygen support, or high flow oxygen non-invasive ventilation. The patients receive a single infusion of CD24Fc or placebo at the beginning of the trial and are followed for up for 28 days thereafter to determine the time to clinical improvement. Because the drug works through a novel mechanism that does not duplicate that of other experimental therapeutics, patients enrolled in other trials need not be excluded. The Phase III trial will enroll a total of 230 patients randomized into blinded CD24Fc or placebo arms, with time to clinical improvement from severe or critical to mild symptoms as the primary endpoint (ClinicalTrials.gov Identifier: NCT04317040).

“We have seen neither infusion reactions nor other drug-related adverse events associated with the trial in first 70 patients. The mortality rate so far is 5%, which is considered low among severe and critical COVID-19 patients. The preliminary results show that the safety of the drug is outstanding for this indication,” said Dr. Pan Zheng, MD., PhD, Chief Medical Officer of OncoImmune.

About Us

Based in Rockville, Maryland, OncoImmune is a
privately-held, clinical-stage biopharmaceutical
company that is actively engaged in the discovery
and development of biopharmaceuticals for the
treatment of cancer and autoimmune disease.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.